| Home | E-Submission | Sitemap | Contact Us |  
The Korean Journal of Medicine 2009;77(1): 26-34.
진행성 유방암의 맞춤 항암요법의 최신 지견
Personalized therapy for advanced breast cancer using molecular signatures
Kyung Hae Jung
In Korea, breast cancer is the second common cancer in women and many patients suffer from metastatic disease after surgery and adjuvant therapy. Metastatic breast cancer is unlikely to be cured, but it is possible to choose therapeutic options according to clinical factors and tumor biology to avoid unnecessary toxicity and improve efficacy. Hormone receptors and HER2 status are the most important predictive factors and should be evaluated in all breast cancers. Hormonal treatment is preferred for initial treatment of hormone receptor positive metastatic breast cancer due to its more favorable side effect profile. Tamoxifen has been the mainstay of hormonal treatment. However, new aromatase inhibitors challenge tamoxifen as the first line therapy in postmenopausal women. Trastuzumab with conventional chemotherapy is the standard of care in patients with strong overexpression of HER2 and lapatinib is active after trastuzumab failure. (Korean J Med 77:26-34, 2009)
Keywords: Breast cancer; Metastasis; Therapy; Hormone; HER2
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Supplementary Material  Supplementary Material
Hormone Therapy for Metastatic Breast Cancer  2017 June;92(3)
Anti-Cancer Therapy of Advanced Lung Cancer in Elderly Patients  2014 November;87(5)
Chemotherapy for Advanced Gastric Cancer in Elderly Patients  2014 November;87(5)
Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6791   Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Association of Internal Medicine. All rights reserved.                powerd by m2community